Abstract
In addition to a variety of other techniques used in T-cell epitope identification, mass spectrometery coupled to liquid chromatography have now become an important and sensitive tool in separation, detection, and sequence analysis of highly complex natural major histocompatibility complex (MHC) ligand mixtures. In this article, we present current strategies for the identification of MHC eluted peptides using high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) with a particular recall to those presented in the context of the non classical human leukocytes antigen (HLA) class I molecule HLA-E. In addition we also discuss the advantages and disadvantages of the methods available in the literature to concentrate and fractionate the peptides prior to analysis by mass spectrometry. An application of our method for isolation and characterization of peptides presented in the context of HLA-E is finally reported.
Keywords: High-performance liquid chromatography, HLA-E, mass- spectrometry, peptides
Current Pharmaceutical Design
Title: HPLC and MS Analysis for the Identification and Characterisation of Peptides Presented in the Context of the Non-Classical Human Leukocytes Antigen (HLA) Class I Molecule HLA-E
Volume: 15 Issue: 28
Author(s): Enrico Millo and Gianluca Damonte
Affiliation:
Keywords: High-performance liquid chromatography, HLA-E, mass- spectrometry, peptides
Abstract: In addition to a variety of other techniques used in T-cell epitope identification, mass spectrometery coupled to liquid chromatography have now become an important and sensitive tool in separation, detection, and sequence analysis of highly complex natural major histocompatibility complex (MHC) ligand mixtures. In this article, we present current strategies for the identification of MHC eluted peptides using high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS) with a particular recall to those presented in the context of the non classical human leukocytes antigen (HLA) class I molecule HLA-E. In addition we also discuss the advantages and disadvantages of the methods available in the literature to concentrate and fractionate the peptides prior to analysis by mass spectrometry. An application of our method for isolation and characterization of peptides presented in the context of HLA-E is finally reported.
Export Options
About this article
Cite this article as:
Millo Enrico and Damonte Gianluca, HPLC and MS Analysis for the Identification and Characterisation of Peptides Presented in the Context of the Non-Classical Human Leukocytes Antigen (HLA) Class I Molecule HLA-E, Current Pharmaceutical Design 2009; 15 (28) . https://dx.doi.org/10.2174/138161209789105126
DOI https://dx.doi.org/10.2174/138161209789105126 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets Recent Advancement in Discovery and Development of Natural Product Combretastatin-inspired Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis The Mechanisms Responsible for Garlic - Drug Interactions and their In Vivo Relevance
Current Drug Metabolism Mechanisms of Action of Imidazoacridinone and Triazoloacridinone Derivatives in View of their Biological Activity
Current Pharmaceutical Analysis Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued) Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology Image-Guided Nanoparticle-Based siRNA Delivery for Cancer Therapy
Current Pharmaceutical Design Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy
Infectious Disorders - Drug Targets Novel Vesicular Drug Delivery System for Topical Delivery of Indomethacin
Drug Delivery Letters TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta
Current Molecular Medicine DNA Methylation and miRNAs Regulation in Hereditary Breast Cancer: Epigenetic Changes, Players in Transcriptional and Post- Transcriptional Regulation in Hereditary Breast Cancer
Current Molecular Medicine Dendrimers and the Development of New Complex Nanomaterials for Biomedical Applications
Current Medicinal Chemistry The Mechanism in Gastric Cancer Chemoprevention by Allicin
Anti-Cancer Agents in Medicinal Chemistry Advances in Biomarker Research for Pancreatic Cancer
Current Pharmaceutical Design Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology